CDMO Ardena has committed to a substantial expansion of its bioanalytical services in the Netherlands.
Through this investment, Ardena will gain an all-new bioanalytical lab at its Oss facility.
This is coupled with the additional capacity and new GLP capabilities added to its Bioanalytical Center of Excellence in Assen.
By investing in its bioanalytical service offering, Ardena hopes to meet the rising demands of the pharmaceutical industry in this area.
Ardena's new 3,000 sqft lab in Oss is expected to be operational by early 2025, and will provide customer with advanced analytical testing services for both small and large molecules.
The facility will utilise LC-MS/MS and flurorometric detection assays, as well as an ELISA-based Gyrolab automated technology platform.
Meanwhile, Ardena's investments into its Assen facility will expand its immunochemistry, flow cytometry capabilities, while also bolstering its qPCR platforms and increasing its LC-MS/MS capacity.
Adding the Oss lab complements Ardena's current bioanalytical operations in Assen, speeding up turnaround times and allowing the CDMO to better meet customer needs.
Ardena's bioanalytical services are suitable for a wide range of clients, and are relevant to every phase of drug development across a plethoraof modalities.
This includes small molecules, therapeutic peptides, antibodies, antibody-drug conjugates (ADCs), nanoparticles, oligonucleotides, mRNA and CGTs.
CEO of Ardena, Jeremie Trochu, commented: “This expansion allows us to quickly scale our operations, leverage an additional pool of talented professionals, and bring enhanced efficiency and value to our clients, from discovery to late stage clinical phases,”
These investments come on the heels of Ardena’s recent announcement to acquire an advanced drug product manufacturing facility in the US from Catalent.
“Together, these investments demonstrate Ardena's focus on growth and innovation, reinforcing our strategy to assist clients navigate through an ever-increasing complex drug development process and bring life-changing therapies to patients worldwide faster,” added Mr. Trochu.